

Primary glomerular diseases: variations in disease types seen in Africa and Europe

Ikechi Okpechi¹, Maureen Duffield², Charles Swanepoel¹

¹ Division of Nephrology and Hypertension, Department of Medicine

² Division of Pathology, Department of Clinical Laboratory Services
Groote Schuur Hospital, University of Cape Town. Cape Town. South Africa.

Received for publication: 05/01/2012
Accepted: 20/01/2012

ABSTRACT

Glomerular diseases account for a significant number of patients with chronic kidney disease worldwide. IgA nephropathy (IgAN) is the predominant primary glomerular disease (PGD) seen across Europe, whereas in Africa, the prevalence of IgAN is not common. The most frequently described glomerular disease in Africa is mesangiocapillary glomerulonephritis (MCGN). The difference in the prevalence of PGDs seen in Africa and Europe may depend on several factors including genetic, socio-economic and demographic influences. Variations in exposure to infections (hygiene hypothesis) and patterns of Th1 and Th2 responses may also contribute significantly to observed differences.

Key-Words:

Glomerulonephritis in Africa; Glomerulonephritis in Europe; Primary glomerulonephritis.

INTRODUCTION

Africa and Europe differ greatly when socio-demographic, economic and health care factors are considered. Approximately 70% of the least developed countries of the world are in Africa and according to the WHO, health financing per capita total expenditure on health in 2009 for countries of

Africa ranged from as low as US\$3 in the Democratic Republic of Congo to US\$612 in Botswana. In comparison, in Western Europe, average figures ranged well above US\$2,500¹.

The pattern of kidney diseases is available for review in many parts of Europe with national or regional registries of kidney diseases (Table I)²⁻¹¹. Such registries are nonexistent in Africa and data are often limited to case reports or single centre series. The major factor accounting for this situation is the lack of expertise to perform and interpret renal biopsies¹²⁻¹⁵.

The incidence of chronic kidney disease (CKD) and end-stage renal disease (ESRD) continues to rise worldwide because of the diabetic epidemic; however, glomerulonephritis (GN) has been shown to account for a significant proportion of patients with CKD and ESRD. The European Renal Association (ERA-EDTA) annual registry report of 2008 showed that GN accounted for 15% of all incident dialysis patients compared to 20% and 17% for diabetes and hypertension respectively¹⁶. Reports from different countries in Africa show that GN is presumed to be (most not biopsied) responsible for up to 52.1% of patients diagnosed with ESRD¹⁷⁻¹⁹. As Africa continues to battle the scourge of the human immunodeficiency virus (HIV) and the numerous renal diseases associated with it, patterns of primary glomerular diseases (PGD) seen in Africa may be changing. Worldwide, there is

Table I

Categories of renal disease seen across Europe and Africa

Country	Author (Ref)	Type of registry	No of biopsies	1 st GN (%)	2 nd GN (%)	TIN (%)	Vascular (%)	Miscellaneous (%)	ESRD (%)	Undefined (%)
Northern Ireland	Hanko <i>et al</i> ²	Single centre	1,844	49.5	30.4	4.9	2.7	1.1	NA	11.4
Italy	Schena <i>et al</i> ³	National	13,835	59.9	25.4	4.0	3.3	7.4	NA	NA
Czech Republic	Rychlik <i>et al</i> ⁴	National	4,004	59.8	25.4	4.4	3.4	0.4	1.2	4.6
Spain*	Rivera <i>et al</i> ⁵	National	4,824	55.8	20.4	NA	NA	NA	NA	NA
Serbia	Naumovic <i>et al</i> ⁶	Single centre	1,626	64.1	24.8	3.1	4.5	1.5	NA	NA
Macedonia	Polenakovic <i>et al</i> ⁷	Single centre	1,304	54.9	NA	NA	NA	NA	NA	NA
France	Simon <i>et al</i> ⁸	Single centre	1,742	51.5	NA	NA	NA	NA	NA	NA
Romania	Covic <i>et al</i> ⁹	Two centres	606	66.2	26.4	1.5	2.3	3.6	NA	NA
Finland	Wirta <i>et al</i> ¹⁰	Six centres	3,648	NA	NA	NA	NA	NA	NA	NA
Belgium	Mesquita <i>et al</i> ¹¹	Single centre	326	30.4	39.9	6.7	13.2	9.8	NA	NA
Egypt	Barsoum <i>et al</i> ¹²	Single centre	1,234	NA	NA	NA	NA	NA	NA	NA
Senegal	Abdou <i>et al</i> ¹³	Single centre	115	69.5	23.5	NA	NA	NA	NA	7.0
Sudan	Khalifa <i>et al</i> ¹⁴	Single centre	89	NA	NA	NA	NA	NA	NA	NA
South Africa	Okpechi <i>et al</i> ¹⁵	Single centre	1,284	34.3	48.1§	9.7	NA	7.9‡	NA	NA

TIN – Tubulointerstitial nephritis, ESRD – End-stage renal disease, NA – Not available (in some cases, may have been included in other categories)

* – The number of biopsies given is for adults aged ≥15 – 65 yrs only.

§ – Includes diseases classified as vascular nephropathy

‡ – Includes diseases classified as ESRD and undefined GN

evidence for temporal variation in the frequency of primary glomerular diseases (PGD)^{2,9,10,20,21}.

To our knowledge, there has never been a published report comparing the frequencies of PGD in Africa and Europe. The purpose of this review is to compare published results of the frequencies of PGD from renal biopsy registries across a selection of European countries with reports from countries in Africa. We will discuss observed similarities or differences in disease patterns between the two continents and what the implications of variations in frequency of PGD represents for burden of kidney disease in both continents. To do this, we searched PUBMED for publications reporting the results of analysis of either single centre, regional or national renal biopsy registries from countries of Europe and Africa alone. Since our purpose was not to perform a systematic analysis/review, we only included one publication per country. For countries with multiple publications on this subject, the publication with the largest number of subjects was used. Also, due to nonuniformity in presentation of results, only articles presenting data as percentage of total number of biopsies were included. We excluded case series, publications in languages other than English, paediatric renal registry reports

and publications that did not include individual types of PGD in their analysis. Ten publications from Europe and four from Africa were thus selected for comparison.

■ TYPES OF RENAL DISEASE AND REGISTRY IN AFRICA AND EUROPE

Reports from Europe (except Belgium)¹¹ and Africa (except South Africa)¹⁵ show that PGDs are the predominant form of renal disease seen on biopsy, usually accounting for more than half of all biopsies performed (Table I). In South Africa, we have shown that PGDs account for only 34.3% of renal diseases compared to 48.1% reported for all secondary glomerular diseases¹⁵. The major reason for this reversal was shown to be due to the number of renal biopsies performed in patients with HIV which had increased from 6.6% of biopsies performed in 2000 to 25.7% of biopsies performed in 2009¹⁵. The prevalence of HIV infection in Europe is low and Ferreira *et al.*²² in Portugal mention the greater predominance of the less virulent HIV-2 infection. In this study, HIV-2 did not directly cause renal disease. Consequently, HIVAN did not seem to contribute to the pattern of kidney

diseases reported in the European registries. The one exception is Belgium, where HIVAN accounted for 6.7% of all biopsies and 16.9% of secondary glomerular diseases¹¹. Until we begin to see a significant reduction in the incidence and prevalence of HIV infection in sub-Saharan Africa, which has the highest burden of HIV in the world, secondary glomerular diseases due to HIV will continue to rise and will impact on the aetiology of CKD and ESRD in Africa. It will be interesting to see how HIV might dilute the biopsy prevalence of PGD reported in Europe over the next decade, given the high influx of African migrants into Europe.

Only a few of the registries from Europe were from single centres; most were multicentre or national registry reports. Multicentre studies are often nearly impossible to perform in Africa where usually only a few centres have the capacity (manpower and infrastructure) to function effectively. There is therefore a need for the establishment of renal registries across several centres in Africa. This will only happen when comprehensive and integrated actions, led by governments, aided by the private sector, local NGOs and key players at all levels of the health system, begin to take place²³.

INDICATIONS FOR RENAL BIOPSIES: A REFLECTION OF WEALTH AND DISEASE?

As many PGD often present with the nephrotic syndrome, it is not unexpected that this is the main indication for the performance of a renal biopsy in both continents (Table II). From European countries, only in Finland was renal biopsy for nephrotic syndrome much lower than that performed for asymptomatic urinary abnormalities (AUA)¹⁰. As AUA is often detected during medical examinations for other purposes and since the patients with AUA are often otherwise well, the percentage of renal biopsies performed for AUA may therefore hint at the level of healthcare in a country. Thus, several countries in Europe have a fairly high percentage of biopsies performed for patients with AUA compared to countries in Africa. In Senegal, only 1.0% of biopsies is performed for patients with AUA and may be a reflection of the amount of money available for healthcare¹. In contrast to Senegal, Egypt and South Africa spend more on healthcare and therefore have a larger number of renal biopsies performed for patients with AUA; 22.5 and 13.6% of biopsies respectively (Table II).

Table II

Indications for renal biopsy: comparison between Europe and Africa

Country	Author (Ref)	n	NS (%)	ANS (%)	AUA (%)	Haematuria (%)	ARF (%)	CRF (%)
Northern Ireland	Hanko <i>et al</i> ²	1,844	NA	NA	NA	NA	NA	NA
Italy	Schena <i>et al</i> ³	13,835	27.1	5.4	30.8	8.7	9.2	18.8
Czech Republic	Rychlik <i>et al</i> ⁴	4,004	39.3	19.1	36.2	16.5	19.4	21.1
Spain	Rivera <i>et al</i> ⁵ (Age < 15 years)	475	46.3	8.4	21.7	15.4	4.2	3.6
	Rivera <i>et al</i> ⁵ (Age ≥ 15-65 years)	4,715	35.2	4.0	30.7	4.5	10.1	11.5
	Rivera <i>et al</i> ⁵ (Age >65 years)	1,478	38.1	5.5	11.5	0.8	29.1	13.7
Serbia	Naumovic <i>et al</i> ⁶	1,626	53.6	7.4	24.3	5.5	0.6	8.6
Macedonia	Polenakovic <i>et al</i> ⁷	1,304	NA	NA	NA	NA	NA	NA
France	Simon <i>et al</i> ⁸ (1976-1985)	663	22.0	26.0	8.0	6.0	19.0	18.0
	Simon <i>et al</i> ⁸ (1986-1995)	685	24.0	17.0	6.0	6.0	21.0	24.0
	Simon <i>et al</i> ⁸ (1996-2002)	394	16.0	15.0	9.0	4.0	18.0	36.0
Romania	Covic <i>et al</i> ⁹	635	52.3	21.9	3.3	NA	12.4	10.1
Finland	Wirta <i>et al</i> ¹⁰	2,465	16.4	13.8	38.7	13.5	17.6	NA
Belgium	Mesquita <i>et al</i> ¹¹	326	40.9	2.5	53.5	3.0	4.9	NA
Egypt	Barsoum <i>et al</i> ¹²	1,234	31.8	12.0	22.5	3.2	7.4	21.2
Senegal	Abdou <i>et al</i> ¹³	115	67.0	26.5	1.0	1.0	1.5	1.0
Sudan	Khalifa <i>et al</i> ¹⁴	89	NA	NA	NA	NA	NA	NA
South Africa	Okpechi <i>et al</i> ¹⁵	1,284	52.5	5.8	13.6	0.3	21.3	6.4


NS – Nephrotic syndrome, ANS – Acute nephritic syndrome, AUA – Asymptomatic urinary abnormality, ARF – Acute renal failure, CRF – Chronic renal failure, NA – Not available

Also, biopsies performed for haematuria alone are seen to be much higher in Europe than in Africa. Biopsies performed for haematuria alone from studies in Europe is as high as 13.5 and 16.5%, respectively for Finland¹⁰ and the Czech Republic⁴. Only 0.3, 1.0 and 3.2% of biopsies are performed for patients presenting alone with haematuria in South Africa,¹⁵ Senegal¹³ and Egypt¹² respectively. Although this might suggest differences in the clinical manifestations and types of glomerular diseases seen in both continents, it must also be said that local policies on performance of renal biopsy may contribute to these differences. The policy in Cape Town is that patients presenting with haematuria alone will have a urological examination. If no urological pathology is present and renal function is normal, follow-up will be arranged and the patient will not be biopsied. This may also explain the low

frequency of IgA nephropathy (IgAN) reported in South Africa.

■ IGA NEPHROPATHY IS RARE IN BLACK AFRICANS: IS THIS A MYTH OR REALITY?

With a few exceptions, Fig. 1 and Table III clearly show that IgAN is the dominant form of PGD seen in Europe. IgAN accounted for 17.2, 34.5, 34.9, 35.2 and 38.8% of all PGDs reported from Spain, Czech Republic, Finland, Italy and Northern Ireland respectively^{2-5,10}. However, IgAN is not commonly reported in Africans as it only accounted for 2.5 to 5.8% of PGDs for Senegal, Sudan and South Africa. A case report from Senegal and studies from South Africa



GDP** – Gross domestic product (data from WHO 2008) 1; FSGS – Focal segmental glomerulosclerosis; MCGN – Mesangiocapillary GN; IgAN – Immunoglobulin A nephropathy
* – These values represent data in adults only

Figure 1

IgA Nephropathy, FSGS and MCGN patterns in Europe and Africa based on country GDP.

Table III

Primary glomerular diseases: Europe and Africa

Country	Author (Ref)	IgAN (%)	MCD (%)	MGN (%)	MPGN (%)	FSGS (%)	MCGN (%)	CN (%)	PIGN (%)
Northern Ireland	Hanko <i>et al</i> ²	38.8	9.8	29.4	–	5.7	11.2	–	–
Italy	Schena <i>et al</i> ³	35.2	7.8	20.7	8.3	11.8	6.6	4.6	3.1
Czech Republic	Rychlik <i>et al</i> ⁴	34.5	12.5	9.3	11.3	10.8	4.6	3.2	1.3
Spain*	Rivera <i>et al</i> ⁵	17.2	7.1	9.7	NA	10.8	4.6	–	–
Serbia	Naumovic <i>et al</i> ⁶	12.2	7.8	18.9	25.1	18.9	10.0	5.1	2.0
Macedonia	Polenakovic <i>et al</i> ⁷	11.8	7.2	13.5	4.4	9.9	8.4	7.4	12.3
France**	Simon <i>et al</i> ⁸	NA	NA	NA	NA	NA	NA	NA	NA
Romania	Covic <i>et al</i> ⁹	28.9	8.5	11.2	–§	11.5	29.4	7.9	–
Finland	Wirta <i>et al</i> ¹⁰	34.9	5.0	11.6	11.6	3.9	3.8	15.0§§	1.0
Belgium	Mesquita <i>et al</i> ¹¹	21.2	19.1	15.1	4.0	30.3	7.0	–	–
Egypt	Barsoum <i>et al</i> ¹²	NA†	16.5	12.7	15.8	22.6	13.5	2.8	1.6
Senegal	Abdou <i>et al</i> ¹³	2.5	9.0	12.5	2.5	67.0	NA	2.5	4.0
Sudan	Khalifa <i>et al</i> ¹⁴	4.7	10.5	2.3	NA	26.6	22.1	8.2††	NA
South Africa	Okpechi <i>et al</i> ¹⁵	5.8	6.0	18.5	19.2	10.5	20.4	11.4	8.2

§ – Included in IgAN

† – No group with IgAN was given, although IgA deposits was reported in some patients with MPGN and crescentic GN

* – These values represent data in adults only

** – The data was presented as rate per million population

§§ – Includes focal proliferative, endocapillary proliferative and extracapillary proliferative GN

†† – Includes rapidly progressive GN and vasculitis

have previously documented the “rarity” of IgAN in black Africans. Seedat *et al.*²⁴ in an analysis of PGDs in 252 black South Africans found only 2 patients (0.8%) with IgAN. Also, Swanepoel *et al.*²⁵ examined 872 biopsies done over a seven-year period and were only able to demonstrate a prevalence of 3.8% of IgAN and none of these patients were black. In 1999, Diouf *et al.*²⁶ described for the first time a patient diagnosed with IgAN in Senegal. As fig. 1 illustrates, the frequency of IgAN appears to reflect a country’s GDP, as countries with the highest GDP had the highest frequencies of IgAN. The correlation between GDP and type of PGD has also been tested in South America where IgAN was found to occur at higher frequencies in countries like Uruguay and Argentina with high GDP compared to low GDP countries like Peru and Paraguay²⁷. A reciprocal relationship between GDP and MCGN was observed in this hypothesis²⁷.

This may be explained by the “hygiene hypothesis” proposed by David Strachan in 1989 to explain the higher frequency of allergies seen in industrialised countries²⁸. Early and frequent exposure to several infectious agents, common in developing nations, leads to a normal Th1 response. However, better public hygiene and less infections observed in industrialised nations is thought to result in persistence of the Th2 phenotype

which thereby increases the risk for developing allergies. Most proliferative glomerulopathies for example, MCGN (fig. 2A), Mesangialproliferative GN (MPGN), and post-infectious GN (PIGN, fig. 2B) are largely driven by Th1 response and are often found to be quite common in developing countries²⁹. This may explain the high prevalence of MCGN in South Africa, Senegal and Egypt. However, the frequencies we have shown for MPGN and PIGN do not seem to be any different between European and African countries (Table III). In Cape Town, we have anecdotally observed that a significant number of patients from prison, sent for investigation of renal disease, are often found to have MCGN. The causal relationship of MCGN with a prison environment, in our community, needs further investigation.

Evidence for IgAN to be a Th2 dependent process comes from the report of several studies that have shown that in IgAN, Th2 dependent cytokines are mainly produced by the circulating T cells³⁰. In murine models of IgAN, Th2 cytokines have also been shown to alter the glycosylation of IgA³¹. In a hypothesis-generating article, Johnson *et al.* have highlighted factors such as malnutrition, helminthic infections, psychological stress, depression and obesity that can modulate the balance between Th1 and Th2 responses and that can also explain key epidemiological differences seen across the world²⁷. Beyond the mechanisms postulated in this




Figure 2A

Methenamine silver stain x400. Arrow head sited along the peripheral basement membrane to show a double membrane and an interposed mesangial nucleus, diagnostic of mesangiocapillary glomerulonephritis.




Figure 2B

H/E stain x400. Peripheral glomerular loop to show numerous neutrophils within the capillary lumina and in the mesangium, typical of the early phase of acute post streptococcal glomerulonephritis.

hypothesis, they added that differences in biopsy practice, as well as the environmental and genetic effects, may also play an important role leading to identification of IgAN in any population. Although IgAN may not be as common in black Africans as other PGDs, we certainly think that the very low rate of biopsies performed in many centres in Africa (in some cases no biopsies at all) and policies related to performance of biopsy in asymptomatic patients may account for this seemingly “uncommon disease”.

Although genetic factors are thought to contribute to IgAN, multiple genes with modest effect in combination with environmental factors are thought to play a role rather than single genetic defects. Linkage of IgAN to chromosome 6q22-23 (IGAN1), chromosome 4q26-31 (IGAN2) and 17q12-22 (IGAN3) have been reported^{32,33}. However, the study of Gharavi *et al.* showed that, only 60% of patients were linked to IGAN1, suggesting that other genes may be involved³². The exact role of genetic differences between Africans and Europeans, giving rise to the divergent frequencies of IgAN and MCGN is still to be determined.

■ OTHER PRIMARY GLOMERULAR DISEASES

Fig. 1 also shows that focal segmental glomerulosclerosis (FSGS) occurs at higher frequencies in Africans than in Europeans. FSGS is common in people

of African descent and genetic studies have shown a strong association with some genes in African-Americans. The higher frequency of FSGS in Belgium compared to other European countries may be due to the large number of Africans represented in their registry (about 20-30% from 1994)¹¹. The prevalence of primary FSGS has remained stable in Cape Town over the last decade; however, secondary FSGS due to HIV is seen frequently. The observed patterns of other PGDs such as MPGN, PIGN, Minimal Change Disease (MCD), Membranous Glomerulonephritis (MGN) and crescentic GN did not appear to differ much between reports from Europe and Africa.

■ CONCLUSION

Variations in the pattern of PGDs seen in Europe and Africa are more noticeably observed for IgAN, MCGN and FSGS. Although genetic factors could play a role, the influence of socio-economic and demographic factors may contribute substantially to the types of kidney diseases seen in both continents. In order to better understand the types and patterns of kidney diseases seen in Africa, the number and rate of renal biopsies will need to increase across centres in Africa. Due to emigration patterns from Africa, secondary glomerular diseases, mainly due to HIVAN may increase in Europe in the next decade.

Conflict of interest statement. None declared.

References

1. World Health Organization. Health financing per capita total expenditure on health at average exchange rate (US\$), 2009 (Available at: http://gamapserver.who.int/gho/interactive_charts/health_financing/atlas.html?indicator=i3&date=2009) (Accessed 21st December 2011)
2. Hanko JB, Mullan RN, O'Rourke DM, *et al.* The changing pattern of adult primary glomerular disease. *Nephrol Dial Transplant* 2009;24:3050-3054
3. Schena FP. Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. *Nephrol Dial Transplant* 1997;12:418-426
4. Rychlík I, Jancov'a E, Tesar V, *et al.* The Czech registry of renal biopsies. Occurrence of renal diseases in the years 1994-2000. *Nephrol Dial Transplant* 2004;19:3040-3049
5. Rivera F, López-Gómez JM, Pérez-García R, *et al.* Frequency of renal pathology in Spain 1994-1999. *Nephrol Dial Transplant* 2002;17:1594-1602
6. Naumovic R, Pavlovic S, Stojkovic D, *et al.* Renal biopsy registry from a single centre in Serbia: 20 years of experience. *Nephrol Dial Transplant* 2009;24:877-885
7. Polenakovic MH, Grcevska L, Dzíkova S. The incidence of biopsy proven primary glomerulonephritis in the Republic of Macedonia long-term follow-up. *Nephrol Dial Transplant* 2003;18:S26-S27
8. Simon P, Ramee MP, Boulahrouz R, *et al.* Epidemiologic data of primary glomerular diseases in western France. *Kidney Int* 2004;66:905-908
9. Covic A, Schiller A, Volovat C, *et al.* Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. *Nephrol Dial Transplant* 2006;21:419-424
10. Wirta O, Mustonen J, Helin H, Pasternack A. Incidence of biopsy-proven glomerulonephritis. *Nephrol Dial Transplant*. 2008;23:193-200
11. Mesquita M, Fosso C, Bakoto Sol E, *et al.* Renal biopsy findings in Belgium: a retrospective single center analysis. *Acta Clin Belg* 2011;66:104-109
12. Barsoum RS, Francis MR. Spectrum of glomerulonephritis in Egypt. *Saudi J Kidney Dis Transpl* 2000;11:421-429
13. Abdou N, Boucar D, El Hadj, *et al.* Histopathological profiles of nephropathies in senegal. *Saudi J Kidney Dis Transpl* 2003;14:212-214
14. Khalifa EH, Kabbalo BG, Suleiman SM, *et al.* Pattern of glomerulonephritis in Sudan: histopathological and immunofluorescence study. *Saudi J Kidney Dis Transpl* 2004;15:176-179
15. Okpechi I, Swanepoel C, Duffield M, *et al.* Patterns of renal disease in Cape Town South Africa: a 10-year review of a single-centre renal biopsy database. *Nephrol Dial Transplant* 2011;26:1853-1861
16. Stel VS, van de Luitgaarden MW, Wanner C, Jager KJ; on behalf of the European Renal Registry Investigators. The 2008 ERA-EDTA Registry Annual Report-a précis. *NDT Plus* 2011;4:1-13
17. Arogundade FA, Sanusi AA, Akinsola A. Epidemiology of chronic renal failure in Nigeria: Is there a change in trend. *Nephrology* 10:(WCN 2005 Abstracts) 2005;56 (abstr; suppl 1)
18. Matekole M, Affram K, Lee SJ, *et al.* Hypertension and end-stage renal failure in tropical Africa. *J Hum Hypertens* 1993;7:443-446
19. Diouf B, Ka EF, Niang A, *et al.* Etiologies of chronic renal insufficiency in a adult internal medicine service in Dakar. *Dakar Med* 2000;45:62-65
20. Swaminathan S, Leung N, Lager DJ, *et al.* Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. *Clin J Am Soc Nephrol* 2006;1:483-487
21. Zhou F, Zhao M, Zou W, *et al.* The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. *Nephrol Dial Transplant* 2009;24:870-876
22. Ferreira AC, Carvalho D, Carvalho F, *et al.* Renal pathology in Portuguese HIV-infected patients. *Port J Nephrol Hypert* 2011;25:275-283
23. Katz IJ, Gertholtz T, Naicker S. Africa and nephrology: the forgotten continent. *Nephron Clin Pract* 2011;117:c320-7
24. Seedat YK, Nathoo BC, Parag KB, *et al.* IgA nephropathy in blacks and Indians of Natal. *Nephron* 1988;50:137-141
25. Swanepoel CR, Madaus S, Cassidy MJ, *et al.* IgA nephropathy-Groote Schuur Hospital experience. *Nephron* 1989;53:61-4
26. Diouf B, Diao M, Niang A, *et al.* First case of primary IgA glomerulonephritis (Berger's disease) in Senegal. *Dakar Med* 1999;44:140-142
27. Johnson RJ, Hurtado A, Merszei J, Rodriguez-Iturbe B, Feng L. Hypothesis: dysregulation of immunologic balance resulting from hygiene and socioeconomic factors may influence the epidemiology and cause of glomerulonephritis worldwide. *Am J Kidney Dis* 2003;42:575-581.
28. Strachan DP. Hay fever, hygiene, and household size. *BMJ* 1989;299:1259-1260
29. Holdsworth SR, Kitching AR, Tipping PG. Th1 and Th2 T helper subsets affect patterns of injury and outcomes in glomerulonephritis. *Kidney Int* 1999;55:1198-1216
30. Lim CS, Zheng SM, Kim YS, *et al.* Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy. *Nephrol Dial Transplant* 2001;16:269-275
31. Chinatalacharuvu SR, Emancipator SN. The glycosylation of IgA produced by murine B cells is altered by Th2 cytokines. *J Immunol* 1997;159:2327-2333
32. Gharavi AG, Yan Y, Scolari F, *et al.* IgA nephropathy, the most common cause of glomerulonephritis, is linked to 6q22-23. *Nat Genet* 2000;26:354-357
33. Bisceglia L, Cerullo G, Forabosco P, *et al.* Genetic heterogeneity in Italian families with IgA nephropathy: suggestive linkage for two novel IgA nephropathy loci. *Am J Hum Genet* 2006;79:1130-1134

Correspondence to:

Prof. Charles Swanepoel
 Division of Nephrology and Hypertension
 Department of Medicine
 Groote Schuur Hospital, University of Cape Town
 Cape Town, South Africa
 E-mail: Charles.Swanepoel@uct.ac.za